Characterization and Efficacy of a Nanomedical Radiopharmaceutical for Cancer Treatment

Area of Science:

• Oncology
• Nanomedicine
• Radiochemistry

Background:

• Significant unmet clinical need exists for novel cancer therapies, particularly for aggressive, metastatic solid tumors.
• Current treatments face challenges with tumor accessibility and specificity.
• Development of targeted therapies is crucial for improving cancer management.

Purpose of the Study:

• To develop and evaluate a novel radioisotope-labeled nanoparticle, ¹⁷⁷Lu-SN201, for targeted radionuclide therapy of solid tumors.
• To assess the tumor-targeting capabilities and therapeutic efficacy of ¹⁷⁷Lu-SN201.
• To explore the clinical applicability of ¹⁷⁷Lu-SN201 using imaging techniques.

Main Methods:

• Synthesis and characterization of ¹⁷⁷Lu-SN201, a 27 nm nanoparticle labeled with Lutetium-177.
• In vitro evaluation of nanoparticle stealth properties.
• In vivo anti-tumor efficacy studies in mouse models of mammary gland and colon carcinoma.
• Single photon emission computed tomography (SPECT) imaging to assess tumor uptake and biodistribution.

Main Results:

• ¹⁷⁷Lu-SN201 demonstrated robust stealth properties in vitro.
• Significant anti-tumor efficacy was observed in preclinical mouse models.
• SPECT imaging confirmed tumor uptake, with an average of 19.4% injected dose per gram (ID/g).
• The nanoparticle selectively targets solid tumors via the enhanced permeability and retention (EPR) effect.

Conclusions:

• ¹⁷⁷Lu-SN201 is a promising novel agent for radionuclide therapy.
• The nanoparticle exhibits selective tumor targeting and potent anti-tumor activity.
• This agent has the potential for clinical application in treating various solid tumor types.